| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Porgaviximab/Larcaviximab/Cosfroviximab | c2G4-N; c4G7; c13C6 | Phase 3 Clinical | Mapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology Laboratory | Hemorrhagic Fever, Ebola | Details |
| MIL-77 | MIL-77 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical Sciences | Hemorrhagic Fever, Ebola | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ansuvimab | VRC-EBOMAB092-00-AB; MAb114; MAb-114 | Approved | National Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, Islamabad | Ebanga | United States | Hemorrhagic Fever, Ebola | Ridgeback Biotherapeutics Lp | 2020-12-21 | Hemorrhagic Fever, Ebola | Details |
| Atoltivimab/Maftivimab/Odesivimab | REGN3470-3471-3479; REGN-EB3 | Approved | Inmazeb | United States | Hemorrhagic Fever, Ebola | Regeneron Pharmaceuticals Inc | 2020-10-14 | Hemorrhagic Fever, Ebola | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



